中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
9期
1753-1757
,共5页
原癌基因蛋白质c-kit%小细胞肺癌%舒尼替尼%维持治疗
原癌基因蛋白質c-kit%小細胞肺癌%舒尼替尼%維持治療
원암기인단백질c-kit%소세포폐암%서니체니%유지치료
Proto-oncogene proteins c-kit%Small cell lung cancer%Sunitinib%Maintenance treatment
c-kit 蛋白受体是跨膜酪氨酸激酶受体（RTK）家族中的一员，与其配体干细胞因子结合后受体酪氨酸激酶功能区被激活，产生自身磷酸化，完成细胞内外的信号传导，对这些细胞的分化发育以及功能维持起重要作用。近年来研究发现小细胞肺癌（SCLC）存在 c-kit 蛋白受体的异常高表达，推测其突变与SCLC发生存在着一定的联系，本文综述了c-kit蛋白受体在SCLC研究中的进展。小细胞肺癌是高侵袭性疾病，其在所有肺癌的诊断中约占15%～20%，其特点是肿瘤倍增时间快、生长分数高、播散转移早，对一线化学治疗（化疗）和放射治疗（放疗）高度敏感，但是无论疾病程度如何，绝大多数患者最终化疗后会发生疾病复发或化疗耐受，使SCLC化疗后维持治疗成为研究重点。目前，新的靶向药物在临床中的研究让我们看到了方向，分子靶向治疗可能成为化疗后维持治疗的最有效疗法。本文提供了一例舒尼替尼在小细胞肺癌患者化疗后维持治疗的病例，旨在为SCLC化疗后维持治疗提供新的思路。
c-kit 蛋白受體是跨膜酪氨痠激酶受體（RTK）傢族中的一員，與其配體榦細胞因子結閤後受體酪氨痠激酶功能區被激活，產生自身燐痠化，完成細胞內外的信號傳導，對這些細胞的分化髮育以及功能維持起重要作用。近年來研究髮現小細胞肺癌（SCLC）存在 c-kit 蛋白受體的異常高錶達，推測其突變與SCLC髮生存在著一定的聯繫，本文綜述瞭c-kit蛋白受體在SCLC研究中的進展。小細胞肺癌是高侵襲性疾病，其在所有肺癌的診斷中約佔15%～20%，其特點是腫瘤倍增時間快、生長分數高、播散轉移早，對一線化學治療（化療）和放射治療（放療）高度敏感，但是無論疾病程度如何，絕大多數患者最終化療後會髮生疾病複髮或化療耐受，使SCLC化療後維持治療成為研究重點。目前，新的靶嚮藥物在臨床中的研究讓我們看到瞭方嚮，分子靶嚮治療可能成為化療後維持治療的最有效療法。本文提供瞭一例舒尼替尼在小細胞肺癌患者化療後維持治療的病例，旨在為SCLC化療後維持治療提供新的思路。
c-kit 단백수체시과막락안산격매수체（RTK）가족중적일원，여기배체간세포인자결합후수체락안산격매공능구피격활，산생자신린산화，완성세포내외적신호전도，대저사세포적분화발육이급공능유지기중요작용。근년래연구발현소세포폐암（SCLC）존재 c-kit 단백수체적이상고표체，추측기돌변여SCLC발생존재착일정적련계，본문종술료c-kit단백수체재SCLC연구중적진전。소세포폐암시고침습성질병，기재소유폐암적진단중약점15%～20%，기특점시종류배증시간쾌、생장분수고、파산전이조，대일선화학치료（화료）화방사치료（방료）고도민감，단시무론질병정도여하，절대다수환자최종화료후회발생질병복발혹화료내수，사SCLC화료후유지치료성위연구중점。목전，신적파향약물재림상중적연구양아문간도료방향，분자파향치료가능성위화료후유지치료적최유효요법。본문제공료일례서니체니재소세포폐암환자화료후유지치료적병례，지재위SCLC화료후유지치료제공신적사로。
C-kit is a member of the receptor tyrosine kinase subclassⅢfamily. Stem cell factor (SCF) is the cognate ligand for c-kit. When c-kit binds to SCF, the function area of receptor tyrosine kinase will be activated, to complete signal transduction pathways and then play a role in the cell functions including survival, proliferation and adhersion. Recently some studies argue that there is c-kit abnormal high expression in small cell lung cancer (SCLC), and the kinase activity of kit has been implicated in the pathophysiology of SCLC. This article reviewed the study about the potential relationship between c-kit protein and SCLC. SCLC is a highly aggressive disease and represents approximately 15%-20% of all diagnosed lung cancers. Treatment of SCLC remains challenging because of its rapid growth, early dissemination, and development of drug resistance during the course of the disease. SCLC is highly sensitive to radiotherapy and chemotherapy, however, no matter the extent of disease, most of patients will have tumor recurrence or resistance to the chemotherapy in the end, so it’s very important to study the maintenance treatment after chemotherapy for the patients of SCLC. Currently, new targeted drugs have offered several prospects in clinical studies. The most significant advance in the treatment of this challenging disease may be the introduction of molecularly targeted therapies. In this article, we provided a case about the application of sunitinib in SCLC, aimed to investigate a new method about the maintenance treatment after chemotherapy in SCLC.
